Proteomic Analysis of the Myocardium in Hypertrophic Obstructive Cardiomyopathy

Caroline J. Coats, Wendy E. Heywood, Alex Virasami, Nadia Ashrafi, Petros Syrris, Cris Dos Remedios, Thomas A. Treibel, James C. Moon, Luis R. Lopes, Christopher G.A. McGregor, Michael Ashworth, Neil J. Sebire, William J. McKenna, Kevin Mills, Perry M. Elliott

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is characterized by a complex phenotype that is only partly explained by the biological effects of individual genetic variants. The aim of this study was to use proteomic analysis of myocardial tissue to explore the postgenomic phenotype. METHODS: Label-free proteomic analysis was used initially to compare protein profiles in myocardial samples from 11 patients with HCM undergoing surgical myectomy with control samples from 6 healthy unused donor hearts. Differentially expressed proteins of interest were validated in myocardial samples from 65 unrelated individuals (HCM [n=51], controls [n=7], and aortic stenosis [n=7]) by the development and use of targeted multiple reaction monitoring-based triple quadrupole mass spectrometry. RESULTS: In this exploratory study, 1586 proteins were identified with 151 proteins differentially expressed in HCM samples compared with controls ( P<0.05). Protein expression profiling showed that many proteins identified in the initial discovery study were associated with metabolism, muscle contraction, calcium regulation, and oxidative stress. Proteins downregulated in HCM versus controls included creatine kinase M-type, fructose-bisphosphate aldolase A, and phosphoglycerate mutase ( P<0.001). Proteins upregulated in HCM included lumican, carbonic anhydrase 3, desmin, α-actin skeletal, and FHL1 (four and a half LIM domain protein 1; P<0.01). Myocardial lumican concentration correlated with the left atrial area (ρ=0.34, P=0.015), late gadolinium enhancement on cardiac magnetic resonance imaging ( P=0.03) and the presence of a pathogenic sarcomere mutation ( P=0.04). CONCLUSIONS: The myocardial proteome of HCM provides supporting evidence for dysregulation of metabolic and structural proteins. The finding that lumican is raised in HCM hearts provides insight into the myocardial fibrosis that characterizes this disease.

Original languageEnglish (US)
Pages (from-to)e001974
JournalCirculation. Genomic and precision medicine
Volume11
Issue number12
DOIs
StatePublished - Dec 1 2018
Externally publishedYes

Keywords

  • cardiomyopathies
  • fibrosis
  • hypertrophy
  • proteome

Fingerprint Dive into the research topics of 'Proteomic Analysis of the Myocardium in Hypertrophic Obstructive Cardiomyopathy'. Together they form a unique fingerprint.

  • Cite this

    Coats, C. J., Heywood, W. E., Virasami, A., Ashrafi, N., Syrris, P., Dos Remedios, C., Treibel, T. A., Moon, J. C., Lopes, L. R., McGregor, C. G. A., Ashworth, M., Sebire, N. J., McKenna, W. J., Mills, K., & Elliott, P. M. (2018). Proteomic Analysis of the Myocardium in Hypertrophic Obstructive Cardiomyopathy. Circulation. Genomic and precision medicine, 11(12), e001974. https://doi.org/10.1161/CIRCGEN.117.001974